Fernandez Maria Luz, Webb Densie
Department of Nutritional Sciences, University of Connecticut, Storrs, CT 06269, USA.
J Am Coll Nutr. 2008 Feb;27(1):1-5. doi: 10.1080/07315724.2008.10719668.
The current National Cholesterol Education Program Adult Treatment Panel III guidelines recommend specific target levels of LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C) for determining cardiovascular disease (CVD) risk and evaluating the effectiveness of lipid-lowering therapies. While there is a growing consensus that levels of apolipoprotein (apo) B and the ratio of apo B/apo A-I are more accurate predictors of CVD risk, the question has been raised as to whether it is realistic to expect patients and health professionals to switch from cholesterol-based guidelines to apolipoprotein-based guidelines. Because it will take time before apolipoprotein terminology is recognized by the general public and recommended by the NCEP Adult Treatment panel to evaluate risk, it may be more efficacious to continue adhering to the already familiar and proven measurements of the LDL-C/HDL-C ratio. The following review provides evidence that the LDL-C/HDL-C ratio continues to be a valuable and standard tool to evaluate CVD risk in all populations.
当前的美国国家胆固醇教育计划成人治疗专家组第三次报告指南推荐了低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)的特定目标水平,用于确定心血管疾病(CVD)风险以及评估降脂治疗的效果。虽然越来越多的人达成共识,即载脂蛋白(apo)B水平和apo B/apo A-I比值是更准确的CVD风险预测指标,但有人提出疑问,期望患者和医疗专业人员从基于胆固醇的指南转向基于载脂蛋白的指南是否现实。由于载脂蛋白术语被公众认可并被美国国家胆固醇教育计划成人治疗专家组推荐用于评估风险还需要时间,继续坚持已经熟悉且经过验证的LDL-C/HDL-C比值测量方法可能更有效。以下综述提供了证据,表明LDL-C/HDL-C比值仍然是评估所有人群CVD风险的有价值的标准工具。